Skip to main content

Branded

  • Reports: Analysis finds steep rise in ADHD diagnoses among children

    NEW YORK — More than one-tenth of school-age children and nearly one-fifth of high school boys in the United States have received a diagnosis for attention deficit hyperactivity disorder, according to published reports.

    The New York Times reported that the dramatic rise in the number of children diagnosed with ADHD over the last decade could lead to concern of over-diagnosis of the condition, as well as overuse of medications to treat it. The Times based its report on an analysis of raw data from the Centers for Disease Control and Prevention.

  • Federal court rules in favor of Actavis in generic asthma drug case

    PARSIPPANY, N.J. — A court has ruled in favor of generic drug maker Actavis concerning its generic version of a drug to treat asthma in children, the company said.

  • Reports: Indian Supreme Court strikes down leukemia drug patent

    NEW YORK — A ruling by India's high court means cheaper generic versions of a cancer drug will remain available in developing countries, according to published reports.

    The New York Times reported that the Indian Supreme Court ruled drug companies there could keep making generic versions of Swiss drug maker Novartis' leukemia medication Gleevec (imatinib). According to the Times, generic versions of Gleevec in India cost about $2,500 per year, compared with $70,000 per year for the branded version.

  • Infants receive GERD medication more often than necessary, study finds

    ANN ARBOR, Mich. — Symptoms associated with gastroesophageal reflux disease are frequently overtreated in infants, according to a new study by researchers in Michigan and Missouri.

    The study, published online Monday in the journal Pediatrics, found that doctors often diagnose such common symptoms in infants as crying and spitting up as disease, and frequent diagnoses of GERD can lead to overuse of medications to treat it, said the researchers at the University of Michigan and the University of Missouri.

  • FDA approves new Teva contraceptive

    JERUSALEM — The Food and Drug Administration has approved a new contraceptive therapy made by Teva Pharmaceutical Industries, Teva said Monday.

    The drug maker announced the approval of Quartette (levonorgestrel, ethinyl estradiol and ethinyl estradiol) tablets. Teva said the drug represented the "next generation" of extended-regimen oral contraceptives and was designed to minimize breakthrough bleeding between scheduled periods.

  • Pharmaca introduces travel vaccination, health consultation program

    BOULDER, Colo. — Pharmaca Integrative Pharmacy on Thursday expanded its immunization offering to include travel vaccinations along with a comprehensive list of health services related to traveling abroad. 

    Pharmaca patients can now schedule an appointment for any of the following vaccinations: hepatitis A and B, tetanus, typhoid, meningitis, Tdap, yellow fever (though not in Colorado locations), varicella and rabies. Pharmaca still offers vaccinations for flu, shingles, whooping cough and pneumonia on a walk-in basis.

  • FDA approves J&J diabetes drug

    SILVER SPRING, Md. — The Food and Drug Administration has approved a new drug made by Johnson & Johnson for treating Type 2 diabetes, the agency said.

    The FDA announced the approval of J&J subsidiary Janssen Pharmaceuticals' Invokana (canagliflozin) tablets, designed for use with diet and exercise to improve blood-sugar control in adults with the disease.

  • FDA approves Aciphex Sprinkle capsules

    WOODCLIFF LAKE, N.J. — The Food and Drug Administration has approved a treatment made by Eisai for gastroesophageal reflux disease in children ages 1 year to 11 years, the drug maker said.

    Eisai announced the approval of Aciphex Sprinkle (rabeprazole sodium) delayed-release capsules.

X
This ad will auto-close in 10 seconds